<?xml version="1.0" encoding="UTF-8"?>
<p>To date there are no licensed vaccines for RSV. However, strategies to protect the young infant through immunisation are underway. One approach showing particular promise is to protect the infant over the first few months of life by maternal vaccination. A maternal RSV vaccine which is based on a post-fusion F protein nanoparticle design 
 <sup>
  <xref rid="ref-7" ref-type="bibr">7</xref>
 </sup>, is now undergoing phase 3 clinical trials ( 
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02624947" xmlns:xlink="http://www.w3.org/1999/xlink">NCT02624947</ext-link>). Standardised serological assays are needed if this or other vaccines show good efficacy as they go to effectiveness phase 3b/4 clinical trials.
</p>
